{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T11:26:53Z","timestamp":1715599613946},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2010,5,29]],"date-time":"2010-05-29T00:00:00Z","timestamp":1275091200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Cardio Med"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1007\/s11936-010-0077-6","type":"journal-article","created":{"date-parts":[[2010,5,28]],"date-time":"2010-05-28T02:52:07Z","timestamp":1275015127000},"page":"396-407","source":"Crossref","is-referenced-by-count":8,"title":["Do We Know When and How to Lower Lipoprotein(a)?"],"prefix":"10.1007","volume":"12","author":[{"given":"Parag H.","family":"Joshi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Krivitsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gustavo","family":"Vazquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Szilard","family":"Voros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,5,29]]},"reference":[{"issue":"15","key":"77_CR1","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","volume":"350","author":"CP Cannon","year":"2004","unstructured":"Cannon CP, Braunwald E, McCabe CH, et al.: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004, 350(15):1495\u20131504.","journal-title":"N Engl J Med"},{"issue":"4","key":"77_CR2","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","volume":"302","author":"S Erqou","year":"2009","unstructured":"Erqou S, Kaptoge S, Perry PL, et al.: Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009, 302(4):412\u2013423.","journal-title":"JAMA"},{"issue":"26","key":"77_CR3","doi-asserted-by":"crossref","first-page":"23260","DOI":"10.1074\/jbc.M302780200","volume":"278","author":"MA Hancock","year":"2003","unstructured":"Hancock MA, Boffa MB, Marcovina SM, et al.: Inhibition of plasminogen activation by lipoprotein(a): critical domains in apolipoprotein(a) and mechanism of inhibition on fibrin and degraded fibrin surfaces. J Biol Chem 2003, 278(26):23260\u201323269.","journal-title":"J Biol Chem"},{"issue":"4","key":"77_CR4","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/hmg\/2.4.361","volume":"2","author":"YY Hoek van der","year":"1993","unstructured":"van der Hoek YY, Wittekoek ME, Beisiegel U, et al.: The apolipoprotein(a) kringle IV repeats which differ from the major repeat kringle are present in variably-sized isoforms. Hum Mol Genet 1993, 2(4):361\u2013366.","journal-title":"Hum Mol Genet"},{"issue":"26","key":"77_CR5","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","volume":"361","author":"R Clarke","year":"2009","unstructured":"Clarke R, Peden JF, Hopewell JC, et al.: Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 2009, 361(26):2518\u20132528.","journal-title":"N Engl J Med"},{"issue":"50","key":"77_CR6","doi-asserted-by":"crossref","first-page":"32403","DOI":"10.1074\/jbc.271.50.32403","volume":"271","author":"C Brunner","year":"1996","unstructured":"Brunner C, Lobentanz EM, Petho-Schramm A, et al.: The number of identical kringle IV repeats in apolipoprotein(a) affects its processing and secretion by HepG2 cells. J Biol Chem 1996, 271(50):32403\u201332410.","journal-title":"J Biol Chem"},{"issue":"2","key":"77_CR7","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1159\/000472175","volume":"4","author":"HG Kraft","year":"1996","unstructured":"Kraft HG, Lingenhel A, Pang RW, et al.: Frequency distributions of apolipoprotein(a) kringle IV repeat alleles and their effects on lipoprotein(a) levels in Caucasian, Asian, and African populations: the distribution of null alleles is non-random. Eur J Hum Genet 1996, 4(2):74\u201387.","journal-title":"Eur J Hum Genet"},{"issue":"1","key":"77_CR8","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0021-9150(03)00143-6","volume":"169","author":"FS Geethanjali","year":"2003","unstructured":"Geethanjali FS, Luthra K, Lingenhel A, et al.: Analysis of the apo(a) size polymorphism in Asian Indian populations: association with Lp(a) concentration and coronary heart disease. Atherosclerosis 2003, 169(1):121\u2013130.","journal-title":"Atherosclerosis"},{"issue":"12","key":"77_CR9","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1016\/S0022-2275(20)37461-7","volume":"37","author":"SM Marcovina","year":"1996","unstructured":"Marcovina SM, Albers JJ, Wijsman E, et al.: Differences in Lp[a] concentrations and apo[a] polymorphs between black and white Americans. J Lipid Res 1996, 37(12):2569\u20132585.","journal-title":"J Lipid Res"},{"key":"77_CR10","first-page":"345","volume-title":"Handbook of Lipoprotein Testing","author":"SM Marcovina","year":"2000","unstructured":"Marcovina SM, Koschinsky ML: Lipoprotein(a): structure, measurement, and clinical significance. In Handbook of Lipoprotein Testing, edn 2nd. By Rifai N, Warnick GR, Dominiczak MH. Washington: AACC Press; 2000:345\u2013368.","edition":"2"},{"issue":"14","key":"77_CR11","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1001\/jama.283.14.1845","volume":"283","author":"MG Shlipak","year":"2000","unstructured":"Shlipak MG, Simon JA, Vittinghoff E, et al.: Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA 2000, 283(14):1845\u20131852.","journal-title":"JAMA"},{"issue":"10","key":"77_CR12","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1161\/01.CIR.97.10.979","volume":"97","author":"MA Espeland","year":"1998","unstructured":"Espeland MA, Marcovina SM, Miller V, et al.: Effect of postmenopausal hormone therapy on lipoprotein(a) concentration. PEPI Investigators. Postmenopausal Estrogen\/Progestin Interventions. Circulation 1998, 97(10):979\u2013986.","journal-title":"Circulation"},{"issue":"11","key":"77_CR13","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1373\/clinchem.2003.023689","volume":"49","author":"SM Marcovina","year":"2003","unstructured":"Marcovina SM, Koschinsky ML, Albers JJ, Skarlatos S: Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: recent advances and future directions. Clin Chem 2003, 49(11):1785\u20131796.","journal-title":"Clin Chem"},{"key":"77_CR14","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1080\/10976640601153077","volume":"9","author":"H Sattar","year":"2007","unstructured":"Sattar H, Christian K, Harmon MP, et al.: High-resolution cardiovascular magnetic resonance imaging of the carotid arteries reliably detects very significant early atherosclerosis in patients with elevated Lp(a). J Cardiovasc Magn Res 2007, 9:335\u2013336.","journal-title":"J Cardiovasc Magn Res"},{"issue":"6","key":"77_CR15","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1093\/ajcn\/85.6.1527","volume":"85","author":"MJ Shin","year":"2007","unstructured":"Shin MJ, Blanche PJ, Rawlings RS, et al.: Increased plasma concentrations of lipoprotein(a) during a low-fat, high-carbohydrate diet are associated with increased plasma concentrations of apolipoprotein C-III bound to apolipoprotein B-containing lipoproteins. Am J Clin Nutr 2007, 85(6):1527\u20131532.","journal-title":"Am J Clin Nutr"},{"issue":"1","key":"77_CR16","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1080\/07315724.2008.10719676","volume":"27","author":"LT Bloedon","year":"2008","unstructured":"Bloedon LT, Balikai S, Chittams J, et al.: Flaxseed and cardiovascular risk factors: results from a double blind, randomized, controlled clinical trial. J Am Coll Nutr 2008, 27(1):65\u201374.","journal-title":"J Am Coll Nutr"},{"issue":"12","key":"77_CR17","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1001\/jama.295.12.1412","volume":"295","author":"S Mora","year":"2006","unstructured":"Mora S, Lee IM, Buring JE, Ridker PM: Association of physical activity and body mass index with novel and traditional cardiovascular biomarkers in women. JAMA 2006, 295(12):1412\u20131419.","journal-title":"JAMA"},{"issue":"8","key":"77_CR18","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1001\/archinte.160.8.1177","volume":"160","author":"JR Guyton","year":"2000","unstructured":"Guyton JR, Blazing MA, Hagar J, et al.: Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group. Arch Intern Med 2000, 160(8):1177\u20131184.","journal-title":"Arch Intern Med"},{"issue":"1","key":"77_CR19","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.atherosclerosis.2008.11.026","volume":"205","author":"A Linke","year":"2009","unstructured":"Linke A, Sonnabend M, Fasshauer M, et al.: Effects of extended-release niacin on lipid profile and adipocyte biology in patients with impaired glucose tolerance. Atherosclerosis 2009, 205(1):207\u2013213.","journal-title":"Atherosclerosis"},{"issue":"12","key":"77_CR20","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1111\/j.1742-1241.2008.01938.x","volume":"62","author":"D Maccubbin","year":"2008","unstructured":"Maccubbin D, Bays HE, Olsson AG, et al.: Lipid-modifying efficacy and tolerability of extended-release niacin\/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. Int J Clin Pract 2008, 62(12):1959\u20131970.","journal-title":"Int J Clin Pract"},{"issue":"4","key":"77_CR21","first-page":"687","volume":"157","author":"SL Airan-Javia","year":"2009","unstructured":"Airan-Javia SL, Wolf RL, Wolfe ML, et al.: Atheroprotective lipoprotein effects of a niacin-simvastatin combination compared to low- and high-dose simvastatin monotherapy. Am Heart J 2009, 157(4):687\u2013688.","journal-title":"Am Heart J"},{"issue":"10","key":"77_CR22","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/j.amjcard.2008.02.092","volume":"101","author":"CM Ballantyne","year":"2008","unstructured":"Ballantyne CM, Davidson MH, McKenney J, et al.: Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study). Am J Cardiol 2008, 101(10):1428\u20131436.","journal-title":"Am J Cardiol"},{"issue":"2","key":"77_CR23","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.atherosclerosis.2006.11.037","volume":"192","author":"JM McKenney","year":"2007","unstructured":"McKenney JM, Jones PH, Bays HE, et al.: Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study). Atherosclerosis 2007, 192(2):432\u2013437.","journal-title":"Atherosclerosis"},{"issue":"1","key":"77_CR24","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2147\/vhrm.2006.2.1.87","volume":"2","author":"M Sharma","year":"2006","unstructured":"Sharma M, Sharma DR, Singh V, et al.: Evaluation of efficacy and safety of fixed dose lovastatin and niacin(ER) combination in Asian Indian dyslipidemic patients: a multicentric study. Vasc Health Risk Manag 2006, 2(1):87\u201393.","journal-title":"Vasc Health Risk Manag"},{"issue":"8A","key":"77_CR25","doi-asserted-by":"crossref","first-page":"44B","DOI":"10.1016\/j.amjcard.2008.02.031","volume":"101","author":"AM Scanu","year":"2008","unstructured":"Scanu AM, Bamba R: Niacin and lipoprotein(a): facts, uncertainties, and clinical considerations. Am J Cardiol 2008, 101(8A):44B\u201347B.","journal-title":"Am J Cardiol"},{"issue":"1","key":"77_CR26","doi-asserted-by":"crossref","first-page":"37","DOI":"10.5551\/jat.1651","volume":"17","author":"T Nozue","year":"2010","unstructured":"Nozue T, Michishita I, Mizuguchi I: Effects of ezetimibe on remnant-like particle cholesterol, lipoprotein (a), and oxidized low-density lipoprotein in patients with dyslipidemia. J Atheroscler Thromb 2010, 17(1):37\u201344.","journal-title":"J Atheroscler Thromb"},{"issue":"12","key":"77_CR27","doi-asserted-by":"crossref","first-page":"29U","DOI":"10.1016\/S0002-9149(98)00732-2","volume":"82A","author":"JM Morgan","year":"1998","unstructured":"Morgan JM, Capuzzi DM, Guyton JR: A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients. Am J Cardiol 1998, 82A(12):29U\u201334U.","journal-title":"Am J Cardiol"},{"issue":"22","key":"77_CR28","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa0907569","volume":"361","author":"AJ Taylor","year":"2009","unstructured":"Taylor AJ, Villines TC, Stanek EJ, et al.: Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009, 361(22):2113\u20132122.","journal-title":"N Engl J Med"},{"issue":"6","key":"77_CR29","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/sj.clpt.6100180","volume":"81","author":"E Lai","year":"2007","unstructured":"Lai E, De Lepeleire I, Crumley TM, et al.: Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subtype 1. Clin Pharmacol Ther 2007, 81(6):849\u2013857.","journal-title":"Clin Pharmacol Ther"},{"issue":"22","key":"77_CR30","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1001\/jama.1995.03530220037029","volume":"274","author":"VM Maher","year":"1995","unstructured":"Maher VM, Brown BG, Marcovina SM, et al.: Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). JAMA 1995, 274(22):1771\u20131774.","journal-title":"JAMA"},{"issue":"2","key":"77_CR31","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jacc.2008.04.009","volume":"52","author":"DJ Suk","year":"2008","unstructured":"Suk DJ, Rifai N, Buring JE, Ridker PM: Lipoprotein(a), hormone replacement therapy, and risk of future cardiovascular events. J Am Coll Cardiol 2008, 52(2):124\u2013131.","journal-title":"J Am Coll Cardiol"},{"issue":"14","key":"77_CR32","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1001\/archinte.161.14.1772","volume":"161","author":"PJ Manning","year":"2001","unstructured":"Manning PJ, Allum A, Jones S, et al.: The effect of hormone replacement therapy on cardiovascular risk factors in type 2 diabetes: a randomized controlled trial. Arch Intern Med 2001, 161(14):1772\u20131776.","journal-title":"Arch Intern Med"},{"issue":"7","key":"77_CR33","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.metabol.2005.02.010","volume":"54","author":"W Insull Jr","year":"2005","unstructured":"Insull Jr W, Davidson MH, Kulkarni PM, et al.: Effects of raloxifene and low-dose simvastatin coadministration on plasma lipids in postmenopausal women with primary hypercholesterolemia. Metabolism 2005, 54(7):939\u2013946.","journal-title":"Metabolism"},{"issue":"18","key":"77_CR34","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1001\/jama.279.18.1445","volume":"279","author":"BW Walsh","year":"1998","unstructured":"Walsh BW, Kuller LH, Wild RA, et al.: Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 1998, 279(18):1445\u20131451.","journal-title":"JAMA"},{"issue":"3","key":"77_CR35","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1161\/01.CIR.0000135582.53444.87","volume":"110","author":"EA Varga","year":"2004","unstructured":"Varga EA, Moll S: Cardiology patient pages. Prothrombin 20210 mutation (factor II mutation). Circulation 2004, 110(3):e15\u2013e18.","journal-title":"Circulation"},{"issue":"6","key":"77_CR36","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1161\/01.ATV.0000018301.91721.94","volume":"22","author":"DM Herrington","year":"2002","unstructured":"Herrington DM, Vittinghoff E, Howard TD, et al.: Factor V Leiden, hormone replacement therapy, and risk of venous thromboembolic events in women with coronary disease. Arterioscler Thromb Vasc Biol 2002, 22(6):1012\u20131017.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"77_CR37","doi-asserted-by":"crossref","first-page":"211","DOI":"10.7326\/0003-4819-152-4-201002160-00005","volume":"152","author":"S Toh","year":"2010","unstructured":"Toh S, Hernandez-Diaz S, Logan R, et al.: Coronary heart disease in postmenopausal recipients of estrogen plus progestin therapy: does the increased risk ever disappear? A randomized trial. Ann Intern Med 2010, 152(4):211\u2013217.","journal-title":"Ann Intern Med"},{"issue":"48","key":"77_CR38","doi-asserted-by":"crossref","first-page":"34111","DOI":"10.1074\/jbc.274.48.34111","volume":"274","author":"A Kagawa","year":"1999","unstructured":"Kagawa A, Azuma H, Akaike M, et al.: Aspirin reduces apolipoprotein(a) (apo(a)) production in human hepatocytes by suppression of apo(a) gene transcription. J Biol Chem 1999, 274(48):34111\u201334115.","journal-title":"J Biol Chem"},{"issue":"9","key":"77_CR39","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1093\/clinchem\/48.9.1454","volume":"48","author":"M Akaike","year":"2002","unstructured":"Akaike M, Azuma H, Kagawa A, et al.: Effect of aspirin treatment on serum concentrations of lipoprotein(a) in patients with atherosclerotic diseases. Clin Chem 2002, 48(9):1454\u20131459.","journal-title":"Clin Chem"},{"issue":"2","key":"77_CR40","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.atherosclerosis.2008.07.019","volume":"203","author":"DI Chasman","year":"2009","unstructured":"Chasman DI, Shiffman D, Zee RY, et al.: Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy. Atherosclerosis 2009, 203(2):371\u2013376.","journal-title":"Atherosclerosis"},{"issue":"5","key":"77_CR41","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S1567-5688(09)71819-7","volume":"10","author":"C Stefanutti","year":"2009","unstructured":"Stefanutti C, D\u2019Alessandri G, Russi G, et al.: Treatment of symptomatic HyperLp(a)lipoproteinemia with LDL-apheresis: a multicentre study. Atheroscler Suppl 2009, 10(5):89\u201394.","journal-title":"Atheroscler Suppl"},{"issue":"7","key":"77_CR42","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.108.786822","volume":"118","author":"E Merki","year":"2008","unstructured":"Merki E, Graham MJ, Mullick AE, et al.: Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice. Circulation 2008, 118(7):743\u2013753.","journal-title":"Circulation"}],"container-title":["Current Treatment Options in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11936-010-0077-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11936-010-0077-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11936-010-0077-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T12:14:16Z","timestamp":1635423256000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11936-010-0077-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5,29]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["77"],"URL":"https:\/\/doi.org\/10.1007\/s11936-010-0077-6","relation":{},"ISSN":["1092-8464","1534-3189"],"issn-type":[{"value":"1092-8464","type":"print"},{"value":"1534-3189","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5,29]]}}}